Medtronic Bullish About Endeavor’s Chances In U.S. Market
This article was originally published in The Gray Sheet
Executive Summary
Medtronic is confident being the late-comer to the U.S. drug-eluting stent market will not hinder its Endeavor zotarolimus-eluting coronary stent gaining market share